CombiGene featured in an article in Nature, one of the world’s leading scientific journals

Dec 14, 2018

The latest number of Nature (Vol. 564, Issue 7735, 13 December 2018) features CombiGene’s operations, and the possibilities of using gene therapy to treat epilepsy. Both CombiGene’s scientific founder, Professor Merab Kokaia, and CEO Jan Nilsson, are quoted.

“CombiGene being featured in Nature like this makes me incredibly happy and proud. It is a clear sign that our research and development is beginning to attract international attention. With this fantastic end of 2018, we will start 2019 stronger and even more inspired,” says CombiGene CEO Jan Nilsson.

Read the entire article here:
https://www.nature.com/magazine-assets/d41586-018-07644-y/d41586-018-07644-y.pdf

Press release >>

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden

Linked In     Twitter      Facebook